KEYMED BIO-B (02162) Income Statement & Earnings

80.300
0.0000.00%

15min DelayNot Open Aug 24 16:08 CST

23.99BMarket Cap26.93P/E (TTM)

KEYMED BIO-B (02162) Income Statement

Cumulative·All

YOY

Hide blank lines

Currency: CNY

2026/H1

2025/FY

2025/H1

2024/FY

2024/H1

2023/FY

2023/H1

2022/FY

2022/H1

2021/FY

2021/H1

2020/FY

2019/FY

Total Revenue

+23.72%617.07M

+67.31%716.31M

+812.10%498.75M

+20.91%428.12M

-83.28%54.68M

+253.87%354.10M

+227.12%327.12M

-9.26%100.06M

--100.00M

--110.27M

----

Operating Revenue

+23.72%617.07M

+67.31%716.31M

+812.10%498.75M

+20.91%428.12M

-83.28%54.68M

+253.87%354.10M

+227.12%327.12M

-9.26%100.06M

--100.00M

--110.27M

----

Cost of Revenue

-254.71%-118.74M

-621.70%-88.05M

-796.04%-33.48M

+66.92%-12.20M

+75.12%-3.74M

-1326.62%-36.88M

-491.92%-15.02M

+84.97%-2.59M

---2.54M

---17.20M

----

Cost of Goods Sold

-254.71%-118.74M

-621.70%-88.05M

-796.04%-33.48M

+66.92%-12.20M

+75.12%-3.74M

-1326.62%-36.88M

-491.92%-15.02M

+84.97%-2.59M

---2.54M

---17.20M

----

Gross Profit

+7.10%498.33M

+51.05%628.27M

+813.27%465.28M

+31.12%415.92M

-83.68%50.95M

+225.42%317.22M

+220.23%312.11M

+4.74%97.48M

--97.46M

--93.07M

----

Operating Expense

-9.51%-642.69M

-18.73%-1.23B

-32.11%-586.85M

-33.72%-1.03B

-33.75%-444.22M

-20.58%-773.29M

-53.49%-332.13M

+83.73%-641.29M

+94.03%-216.39M

-366.28%-3.94B

---3.62B

-377.15%-845.42M

---177.18M

Selling Expenses

-58.74%-218.39M

-190.35%-321.99M

-491.78%-137.58M

---110.90M

---23.25M

----

Administrative Expenses

+4.15%-85.55M

+3.05%-182.21M

+0.77%-89.26M

-6.17%-187.93M

-9.20%-89.95M

-32.18%-177.01M

-61.36%-82.37M

-44.84%-133.91M

-90.22%-51.05M

-329.06%-92.45M

---26.84M

-42.16%-21.55M

---15.16M

Research and Development Expenses

+5.91%-338.75M

+1.59%-723.53M

-8.76%-360.02M

-23.30%-735.19M

-32.54%-331.03M

-17.52%-596.28M

-52.28%-249.76M

-41.66%-507.37M

+14.16%-164.01M

-181.13%-358.16M

---191.06M

-96.57%-127.40M

---64.81M

Revaluation Surplus

----

-399.70%-3.48B

---3.40B

-616.44%-696.47M

---97.21M

-Changes in The Fair Value of Other Assets

----

-399.70%-3.48B

---3.40B

-616.44%-696.47M

---97.21M

Operating Interest Expense

----

+77.97%-1.33M

---11.13M

---6.04M

----

Special Items of Operating Income

+2975.30%1.66B

-27.67%96.32M

-26.42%53.94M

+9.25%133.17M

-7.90%73.31M

-52.81%121.89M

-38.89%79.60M

+701.51%258.32M

+518.93%130.26M

-205.05%-42.95M

--21.05M

+166.36%40.88M

--15.35M

Operating Profit

+2339.29%1.51B

-3.76%-503.14M

+78.86%-67.64M

-45.11%-484.93M

-637.05%-319.96M

-17.06%-334.18M

+425.61%59.58M

+92.66%-285.49M

+100.31%11.34M

-383.74%-3.89B

---3.60B

-397.14%-804.54M

---161.84M

Financing Cost

+14.55%-6.38M

+8.41%-16.91M

+15.80%-7.46M

-6.96%-18.46M

+5.07%-8.86M

-105.54%-17.26M

---9.34M

---8.40M

----

-152.05%-14.31M

---5.68M

Share of Profit from Joint Venture Company

+29.15%-401.00K

+87.18%-674.00K

+66.67%-566.00K

-10.70%-5.26M

+19.03%-1.70M

+51.11%-4.75M

+76.20%-2.10M

-1250.63%-9.71M

---8.81M

---719.00K

----

Pretax Profit

+2092.71%1.51B

-2.37%-520.72M

+77.11%-75.66M

-42.80%-508.65M

-786.52%-330.52M

-17.32%-356.19M

+1807.49%48.15M

+92.20%-303.60M

+100.07%2.52M

-375.38%-3.89B

---3.63B

-388.83%-818.85M

---167.51M

Special Items of Pretax Income

----

---27.75M

----

Tax

-9155.31%-290.15M

+70.06%-1.87M

+48.43%-3.14M

-291.98%-6.26M

---6.08M

---1.60M

----

Net Profit

+1645.21%1.22B

-1.49%-522.60M

+76.59%-78.80M

-43.92%-514.91M

-799.14%-336.60M

-17.85%-357.79M

+1807.49%48.15M

+92.20%-303.60M

+100.07%2.52M

-375.38%-3.89B

---3.63B

-388.83%-818.85M

---167.51M

Profit from Continuing Operations

+1645.21%1.22B

-1.49%-522.60M

+76.59%-78.80M

-43.92%-514.91M

-799.14%-336.60M

-17.85%-357.79M

+1807.49%48.15M

+92.20%-303.60M

+100.07%2.52M

-375.38%-3.89B

---3.63B

-388.83%-818.85M

---167.51M

Minority Interests

+277.27%166.00K

-86.83%44.00K

-69.01%44.00K

-78.75%334.00K

-87.95%142.00K

-65.21%1.57M

+140.20%1.18M

+184.88%4.52M

-51.73%-2.93M

-1908.68%-5.32M

---1.93M

---265.00K

----

Net Income to Parent Company

+1644.14%1.22B

-1.44%-522.64M

+76.59%-78.84M

-43.38%-515.24M

-816.98%-336.75M

-16.63%-359.36M

+761.15%46.97M

+92.07%-308.12M

+100.15%5.45M

-374.88%-3.89B

---3.63B

-388.67%-818.58M

---167.51M

Net Income to Common Stockholders

+1644.14%1.22B

-1.44%-522.64M

+76.59%-78.84M

-43.38%-515.24M

-816.98%-336.75M

-16.63%-359.36M

+761.15%46.97M

+92.07%-308.12M

+100.15%5.45M

-374.88%-3.89B

---3.63B

-388.67%-818.58M

---167.51M

Basic EPS

+1530.00%4.29

+3.05%-1.91

+76.74%-0.30

-43.80%-1.97

-816.67%-1.29

-16.10%-1.37

+765.38%0.18

+95.12%-1.18

+100.04%0.02

-98.11%-24.17

---54.08

---12.20

----

Diluted EPS

+1516.67%4.25

+3.05%-1.91

+76.74%-0.30

-43.80%-1.97

-816.67%-1.29

-16.10%-1.37

+782.35%0.18

+95.12%-1.18

+100.04%0.02

-98.11%-24.17

---54.08

---12.20

----

Deadline

Jun 30, 2026

Dec 31, 2025

Jun 30, 2025

Dec 31, 2024

Jun 30, 2024

Dec 31, 2023

Jun 30, 2023

Dec 31, 2022

Jun 30, 2022

Dec 31, 2021

Jun 30, 2021

Dec 31, 2020

Dec 31, 2019

Accounting Standard

IAS

Audit Opinions

	2026/H1	2025/FY	2025/H1	2024/FY	2024/H1	2023/FY	2023/H1	2022/FY	2022/H1	2021/FY	2021/H1	2020/FY	2019/FY

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"